# A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

> **NCT04718844** · PHASE1 · COMPLETED · sponsor: **Silence Therapeutics plc** · enrollment: 44 (actual)

## Conditions studied

- Non-transfusion-dependent Thalassemia
- Low Risk Myelodysplastic Syndrome
- Very-Low Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** SLN124
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04718844
- **Lead sponsor:** Silence Therapeutics plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718844, "A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04718844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*